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Abstract 
 
STEVEN FEINGOLD: Improvements in Ultrasound Mediated Drug Delivery using Microbubble 
Contrast Agents and Application in Ex-Vivo Porcine Eyes.  
(Under the direction of Paul A. Dayton, Ph.D.) 
 
 
Ultrasound mediated drug delivery is a growing field which shows great promise.  
However, the ability to uniformly deliver acoustic energy to large 3D volumes of tissue remains a 
challenge for drug delivery.  Additionally, uneven drug loading and large size distributions in 
microbubble contrast agents (MCAs) reduce the ability to control therapeutic dosing. The aim of 
this thesis is to demonstrate improvements in the field through new techniques in producing 
acoustically active drug delivery agents and applying ultrasonic parameters to volumetric 
regions of interest.    The use of a computer controlled motion stage to apply ultrasound to a 3D 
volume of tissue is shown, allowing the uniform delivery of destructive pulses and acoustic 
radiation force.  This technique is demonstrated in a novel application for treating diseases of 
the posterior segment of the eye.  Injections of MCAs loaded with fluorescent dye into the 
suprachoroidal space of ex-vivo porcine globes are used to assess the feasibility of ultrasound 
mediated drug delivery for treating tissues in the rear of the eye.  Also demonstrated is the 
production of MCAs with a controlled size and drug loading distribution for oil soluble 
compounds, which could enable greater control over therapeutic dosing.   
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Background and introduction 
Ultrasound as a therapeutic modality: 
Ultrasound has a long history as a diagnostic imaging modality, but is being increasingly 
pursued as a method for providing therapeutic treatments.  Therapeutic effects may be derived 
directly from the mechanical effects of ultrasound as in HIFU1 or lithotripsy,2 or through 
techniques making use of ultrasound contrast agents.  Modern ultrasound contrast agents 
consist of a core containing high molecular weight gas surrounded by a lipid shell.  These 
micrometer sized lipospheres are known as microbubble contrast agents (MCAs) and are 
currently widely clinically used in Europe and are available in the US for echocardiography,3 with 
clinical trials ongoing for a variety of other diagnostic roles.4   Clinical ultrasound systems 
integrate specific imaging strategies which take advantage of the non-linear properties of MCAs 
to create contrast agent specific images.5  Due to their size, they are restricted to the vascular 
space when administered intravenously.3  
 MCAs have several properties which make them ideal for use in therapeutic ultrasound.  
In the presence of a strong acoustic field, MCAs undergo disruption and destruction along with 
other phenomena such as jetting6 and can cause increased inertial cavitation.7 These events are 
associated with the creation of small holes in cell membranes (sonoporation)8, increases in 
active transport9 and temporary or permanent weakening of the blood brain barrier.10  These 
effects are not currently well understood and are an active area of research8,10.  Because 
ultrasound energy can be focused spatially and controlled temporally, these effects can be 
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highly localized.  When MCAs are administered in combination with other drugs, uptake of the 
drugs can be enhanced locally.11,12  MCAs can be formulated to carry therapeutic molecules 
either within13 or attached to the outside of their encapsulating lipid shell via conjugated 
nanoparticles or liposomes.14,15 Therapeutic molecules may include chemotherapeutics,11 anti-
proliferatives13 and DNA or RNA strands.16,17  In the presence of strong acoustic pulses, the 
disruption of MCAs will result in the localized release of the therapeutic payload.  By adding 
ligands to the exterior lipid surfaces, MCAs can target specific markers expressed by diseased or 
damaged endothelial cells,18,19  allowing MCAs to concentrate at a site of interest to improve 
their diagnostic and therapeutic utility.18-20 
In addition to destruction via strong acoustic pulses, MCAs can be manipulated using 
acoustic radiation force (ARF).  In the presence of an ultrasound field, non-linear oscillators such 
as MCAs will feel a net force in the direction of sound propagation.21  By transmitting low 
intensity-long duration ultrasonic pulses, the net movement is great enough to translate agents 
out of the central flow of a blood vessel and to the vessel wall.22  In addition to moving away 
from the source of the ultrasound MCAs will move laterally towards other MCAs oscillating 
within the acoustic field,23 a phenomenon known as secondary radiation force.  These two 
effects both serve to increase the concentration of MCAs where the ultrasonic energy is applied, 
and have been successfully used in-vivo to improve therapeutic effect14,15 and to improve 
diagnostic molecular imaging.24  
While current methods for incorporating drugs into MCAs have proven great promise 
for many therapeutics, the total drug load is relatively small given the size of MCAs, the physical 
properties of their shells, and the dilution that occurs when injecting into the blood stream.  
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Several methods are under investigation for increasing the size and uniformity of the drug 
payload including liposome attachment,25 and multilayer design.26 
 
Challenges in drug delivery to the eye: 
Many applications for therapeutic uses of MCAs have been explored in the literature 
including, but not limited to, treatment of vessels damaged by stent placement,13 treatment of 
Crohn’s disease,16 cancer treatement,11,17 and providing improving insulin sensitivity.27  One 
additional application could be in the treatment of diseases of the posterior portion of the eye.  
These diseases include age-related macular degeneration, diabetic macular edema and 
proliferative vitreoretinopathy.  Delivering drugs to this region of the eye is difficult for several 
reasons including the lack external access, the blood-retinal barrier28 and the choroidal 
circulation29.  Current methods for delivering drugs include eye drops and intravitreal and 
periocular injections.  Eye drops remain popular as a non-invasive technique, but often fail to 
reach the posterior segment of the eye.28  Periocular injections face physical barriers such as the 
sclera and choroidal circulation.29  Intravitreal injections are highly invasive and associated with 
a number of complications including retinal detachment, cataract formation, elevated 
intraocular pressure and opacities of the visual axis.30-32  An alternative location for drug delivery 
is the suprachoroidal space (SCS), a region which lies between the choroidal and scleral layers.  
Injections to this space do not penetrate the choroid or the vitreous and are therefore less 
invasive than intravitreal injections.  Previous studies33,34 have shown that drugs injected into 
the anterior SCS are capable of reaching the posterior portion of the SCS, and are more effective 
and have fewer complications34 than other methods. 
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MCAs present at least two possible methods of improving drug delivery to the posterior 
tissues of the eye.  One method is to use sonoporation and related effects to weaken the blood-
retinal barrier, which has just begun to be investigated.35  An alternate approach utilizes the 
ability for ARF to physically move and concentrate MCAs which could allow for intraocular 
injections to concentrate their payloads in the posterior section.   
The studies presented below investigate the ability of MCAs to move within the SCS and 
whether ARF is able to concentrate MCAs and improve the delivery of a fluorescent dye, which 
features as a stand in for a drug payload.  Also described is an experimental technique for 
generating multilayer MCAs capable of carrying large payloads of therapeutic agents which 
could ultimately be used for delivering drugs within the eye or elsewhere in the body. 
 
Explanation of role and format: 
This thesis is divided into 3 main chapters.  Chapters 1 and 3 are papers which have 
been published in peer-reviewed journals and to which I was a contributing author.  Chapter 2 
represents unpublished work which will be expanded on in the future for submission to a peer-
reviewed journal and is my own project.  For Chapter 1, my role was to collect and process 
ultrasound data, and to create images and videos.  For Chapter 3, I was responsible for 
producing multilayer gas lipospheres at UNC and the collection and analysis of ultrasound data 
and images.   
 
 
 
 
 
 
 
Chapter 1. 
Effect and distribution of contrast medium after injection into the anterior suprachoroidal space 
in ex vivo eyes† 
 
Introduction 
 Diseases of the posterior segment of the eye are among the most common causes of 
blindness. In humans, these diseases include age-related macular degeneration, proliferative 
vitreoretinopathy, diabetic macular edema, and endophthalmitis. Although there are many 
advances in the treatment of these posterior segment diseases, the challenges of drug delivery 
to this part of the eye remain high.28 Eye drops continue to be a mainstay in the treatment of 
ocular disease, but most topical medications do not penetrate the posterior segment.37,38 Local 
therapy of the eye, such as periocular and intravitreal injections, has recently become popular to 
treat ocular disease because they minimize systemic side effects and take advantage of small 
tissue volumes and compartments of the eye.39,40 Natural barriers to ocular drug penetration, 
such as conjunctival lymphatics, sclera, choroidal circulation, and epithelial tight junctions, limit 
the ability of periocular injections to reach posterior target tissues.28,29,41 Instead, ocular 
posterior segment disease, such as choroidal neovascularization, macular degeneration, and 
retinal degeneration, are commonly treated locally by intravitreal or subretinal injections or use 
of sustained release devices. However, these treatment modalities are subject to complications 
such as injection site hemorrhage, retinal detachment, cataract formation, endophthalmitis, 
_____________________________ 
†Published under the same title in Investigative Opthalmology & Visual Science. July 2011 vol. 52 no. 8; 5730-6 
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elevated intraocular pressure, opacities of the visual axis, and local toxicity. 30–32 Therefore, 
alternative sites for drug delivery to the ocular posterior segment are needed.  
 Drug delivery to the suprachoroidal space (SCS), a potential space located between the 
choroid and the sclera,42 avoids many of the disadvantages of other local therapies by eluding 
barriers such as conjunctival lymphatics and the sclera and may avoid complications associated 
with intraocular injections or implants. Furthermore, because the SCS is adjacent to the entire 
choroid and thus the ocular posterior segment, drug delivery using the SCS has the potential for 
wide drug distribution and for reach to posterior target tissues.  
 Recently, studies have demonstrated promise in the use of the SCS as a site for drug 
delivery to the eye. Use of the SCS as a drug delivery site was first described by Einmahl et al.,33 
who placed a poly-ortho ester–sustained drug delivery system in the SCS in rabbits and 
demonstrated sustained delivery in the SCS for 3 weeks.33 Ultrasound was used to track the 
distribution of injected material in this study.33 In 2006, Olsen et al.34 described the use of a 
fiberoptic microcannula to access the SCS in a pig with few complications.34 Sustained ocular 
drug delivery of triamcinolone to the SCS was demonstrated using this cannula, with resulting 
low systemic drug levels. A volume of 12 µL triamcinolone was placed into the SCS by use of the 
flexible catheter, and no side effects were noted with the cannulation procedure or drug; after 
the cannula was removed, the SCS was found to return to a normal configuration.34 
Subconjunctival infusion (1 and 10 µL/min) of gadoliniumdiethylenetriaminopentaacetic acid 
(Gd-DTPA) in rabbits resulted in no ocular posterior segment distribution, whereas anterior 
intrascleral infusion resulted in rapid entry of Gd- DTPA into the SCS. The Gd-DTPA was then 
demonstrated to widely distribute to the posterior segment of the eye by way of the SCS.41 In 
another study in rabbits, up to 100 µL fibrin glue was injected into the SCS, resulting in minimal 
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toxicity and complications.43 Preliminary studies have also demonstrated that large biological 
proteins, such as a human antibody (i.e., bevacizumab), injected into in the SCS in a pig model 
resulted in no inflammation, whereas a similar dose injected intravitreally resulted in 
granulomatous vasculitis and vitreitis.44 Finally, the effectiveness of drug delivery to the SCS was 
demonstrated in a study in which a sustained-release matrix-reservoir cyclosporine device that 
was placed in the SCS resulted in long-term control of uveitis in a naturally occurring model of 
autoimmune uveitis.45 Therefore, the SCS route of delivery may offer a unique avenue for future 
routine injections that are safe and effective in targeting retinal and macular diseases.  
 To further develop the SCS as a site for drug delivery, it is important to determine 
whether injections of medications into the anterior SCS, the most accessible location of the SCS, 
will allow distribution of the drug to the posterior targeted tissue. The SCS can be accessed 
through a small sclerotomy or by microneedles placed 4 to 6 mm posterior to the limbus, but 
the amount of drug distribution to the ocular posterior segment that can be achieved from this 
anterior injection location is not known. Recently, Patel et al.46 described the use of hollow 
microneedles to precisely inject drugs into the SCS. In this study, volumes up to 35 µL prototype 
drugs of particle sizes up to 1000 nm were injected into the porcine SCS. These injections 
resulted in a 7% distribution to the posterior SCS.46 However, appropriate injection volumes, 
area of drug distribution, and effect on the SCS of injections must be further evaluated. 
Furthermore, the duration of drug delivery and the ability of the drug to reach target tissues, 
especially the retina, must be determined for each drug and formulation.  
 The purpose of this study was to evaluate injections into the anterior SCS to determine 
the effect and distribution to the posterior SCS and to determine whether target tissues can be 
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reached. In this study, injection volumes, acute effects of injections on the SCS, and flow 
characteristics of injections in the SCS were determined. 
Methods 
Suprachoroidal Injection Technique 
 Adult porcine ex vivo eyes (Animal Technologies, Tyler, TX) were collected and shipped 
overnight on ice. Canine ex vivo globes were collected at a local animal shelter immediately 
after euthanatization and transported on ice. All globes were used within 24 hours of collection. 
Each globe was cleaned of excess periocular tissue, including conjunctiva, extraocular muscle, 
and orbital fat. Canine and porcine eyes are similar in size (e.g., canine vitreous humor volume is 
approximately 1.7 mL whereas porcine vitreous volume is slightly higher at 2.0 mL47,48), and, 
therefore, the procedures described are applicable to each type of eye. A 2-mm full-thickness 
scleral incision was made 5 mm posterior to the superior limbus to expose the SCS. A 27-gauge 
cannula (Anterior Chamber Cannula; BD Visitec, Waltham, MA) was placed 1 mm into the SCS 
through the scleral incision with the opening of the cannula directed posteriorly. Cyano-acrylate 
tissue adhesive (Pacer Technology, Rancho Cucamonga, CA) was used to seal the sclera incision 
and fixate the cannula to the external sclera. 
 
Latex Distribution 
 Porcine and canine eyes were allowed to warm to room temperature for 30 minutes 
and then were injected with undiluted liquid anatomic latex (Carolina Biological Supply 
Company, Burlington, NC) through the 27-gauge cannula placed in the SCS. The liquid latex was 
injected until injection resistance developed or when disruption of the cyanoacrylate incision 
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seal and reflux of latex through the scleral incision occurred. An injection of approximately 1000 
µL latex was required. Globes were then fixed in 10% buffered formalin (Fisher Scientific, 
Kalamazoo, MI) for 48 hours and sectioned either sagittally or in quadrants (i.e., flat mount) 
after removal of the ocular anterior segment. The retina and choroid were then removed, 
exposing the latex in the SCS and the sclera. High-resolution digital photographs (Nikon D200, 
AF-S DX Micro NIKKOR 85mm f/3.5G ED VR Lens; Nikon USA Inc, Melville, NY) of the eyes were 
analyzed using image analysis software (Elements 4.0, Adobe Photoshop, San Jose, CA; ImageJ 
software [developed by Wayne Rasband, National Institutes of Health, Bethesda, MD; available 
at http://rsb.info.nih.gov/ij/index.html]) to determine overall percentage area of distribution of 
latex to the entire SCS. Results were reported as mean (± SD) of percentage SCS distribution. 
 
SCS Distension 
 Ex vivo canine and porcine eyes were used for this study. SCS cannulation was 
performed as described earlier. During the injection of 250, 500, 800, and 1000 µL (n = 6 eyes 
for each volume) of 0.9% phosphate-buffered saline (Fisher Scientific, Fair Lawn, NJ), high-
frequency (50 MHz) ultrasound (E-technologies, Bettendorf, IA) was used to image the effect 
and distension of the injections on the SCS in real time. The ultrasound probe was positioned 
immediately over the injection site so that the adjacent sclera, SCS, and ciliary body/choroid 
were imaged in real time during the injection. Images were collected, and the maximal distance 
that the SCS was distended when injected with PBS was measured with internal calipers of the 
ultrasound. Results were reported as mean SD of SCS separation in millimeters of six eyes at 
each PBS volume. To determine the effect of physiologic intraocular pressure (IOP) on SCS 
distension after injection and to determine the changes of IOP after SCS injection, this study was 
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repeated in porcine ex vivo eyes (n = 4 per injection volume). After placement of the catheter in 
the SCS as described, a 27-gauge needle was placed through the limbus into the anterior 
chamber, and cyano-acrylate tissue adhesive was used to seal the limbal incision. The needle 
was connected with 0.9% saline-filled tubing to a pressure transducer (MedEx LogiCal 
Transducer, Model MX960; MedExSupply Medical Supplies, Monsey, NY) and an electronic 
monitor, allowing for continuous measurement of IOP. Immediately before injection of 250, 
500, 800, or 1000 µL PBS into the SCS, the IOP was increased to 15 mm Hg by injection of 0.9% 
saline through the 27-gauge anterior chamber needle. Maximal distension of the SCS was 
measured and reported as described using internal calipers of the ultrasound. The IOP (in mm 
Hg) at the time of maximal SCS distension was recorded for each injection volume and reported 
as mean change in IOP (±SD) mm Hg. 
 
Two-Dimensional Ultrasound Contrast Imaging of SCS 
 Porcine ex vivo eyes were used for this study. Using contrast-enhanced ultrasound 
(Mylab70; Biosound Esaote, Inc., Indianapolis, IN), 250, 500, and 800 L microbubble ultrasound 
contrast agent (Targestar-P, Targeson Inc., San Diego, CA) was injected into the anterior 
suprachoroidal space through 27-gauge cannulas placed as described earlier. In real time, 
observations were recorded, including flow characteristics of the contrast agent in the SCS. 
Percentage of maximal distribution in the SCS of contrast agent was determined in the sagittal 
ultrasound plane using image analysis software (Elements 4.0 [Adobe Photoshop]; ImageJ 
1.42q). Results were reported as mean (± SD) of percentage SCS distribution of four eyes at each 
contrast agent volume. Using contrast medium detection software (Qontrast; Biosound Esaote, 
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Inc., Indianapolis, IN), regions of interest were placed over the entire SCS and the posterior SCS, 
and contrast enhancement over time was measured as mean pixel intensity. 
 
Three-Dimensional Ultrasound Contrast Imaging of SCS 
 Porcine ex vivo eyes were imaged using a custom 3D contrast imaging system that 
interfaces a computer-controlled linear motion axis with a clinical ultrasound scanner (Acuson 
Sequoia; Siemens Medical Solutions, Malvern, PA). A 4-MHz (4-C1) transducer and contrast 
imaging (Cadence CPS; Siemens Medical Solutions, Malvern, PA) were used. The porcine eye was 
placed in a water bath, and 250 µL microbubble IOVS, July 2011, Vol. 52, No. 8 Contrast 
Ultrasound of the Suprachoroidal Space 5731 contrast medium was injected through 27-gauge 
catheters placed into the anterior SCS. Dynamic contrast medium inflow was observed in a 
midsagittal plane, followed by 3D imaging of the entire globe to assess spatial distribution of the 
contrast agent. Percentage of maximal distribution in the SCS of contrast agent was determined 
slice by slice using image analysis software (Elements 4.0 [Adobe Photoshop]; ImageJ 1.42q). 
Results were reported as mean ( SD) of percentage SCS distribution of 4 eyes. 
 
Statistical Analysis 
 Statistical analysis of the data was performed using computerized software (JMP 
Statistical Discovery Software, vs 8.0; SAS Inc., Cary, NC). Differences in SCS distension, 
distribution of latex, distribution of contrast media, and contrast medium enhancement were 
analyzed using analysis of variance (ANOVA) with Tukey’s HSD test. Differences between species 
were analyzed using an unpaired t-test. Significance was set at P < 0.05 for all comparisons. 
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Results 
Latex Distribution 
 Liquid anatomic latex was injected into the anterior SCS to determine posterior 
distribution from a single anterior injection. In canine eyes, latex distributed to a mean (± SD) of 
39.9% ± 5.2% of the entire SCS on sagittal sections (n = 4) and 46.8% ± 13.1% of the entire SCS 
when the eyes were sectioned in quadrants (n = 4; Fig. 1). In porcine eyes, latex distributed to a 
mean (± SD) of 54.8% ± 15.4% of the SCS in sagittal sections (n = 4) and 42.1% ± 4.3% of the SCS 
in eyes sectioned in quadrants (n = 4; Fig. 1). There were no significant differences between 
species or sectioning techniques in area of distribution. Latex reached the SCS adjacent to the 
area centralis (i.e., macula) in 9 of 16 (56%) eyes (Fig. 1). 
 
Figure 1. Temporal (t) and nasal (n) sagittal sections of a canine globe showing the 
suprachoroidal distribution of a single injection of blue latex in color (A) and in the “edges” 
function of ImageJ software (B). Canine globe sectioned in quadrants demonstrating distribution 
of blue latex in the SCS in color (C) and in the “edges” function of ImageJ software (D). 
SCS Distension 
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 High-frequency ultrasound was used to image the anterior SCS during injection with 
PBS. The metallic tip of the catheter was visualized in the SCS on the ultrasonic image. On 
injection, the SCS rapidly expanded locally, then dissected posteriorly (Fig. 2). As expected, the 
lower volumes of injection resulted in less distension of the SCS. In the canine eyes, maximum 
mean (± SD) distension of the SCS from injection with 250 µL PBS (1.25 ± 0.07 mm) was 
significantly lower than the maximum distension created from 500 µL PBS (2.25 ± 0.07 mm; P < 
0.02), 800 µL PBS (2.25 ± 0.21 mm; P < 0.02), and 1000 µL PBS (2.7 ± 0.28 mm; P < 0.005; ANOVA 
with Tukey’s HSD; Fig. 3). In the porcine eyes, maximum mean (± SD) distension of the SCS from 
injection with 250 µL PBS (1.57 ± 0.48 mm) was significantly lower than the maximum distension 
created from 800 µL PBS (2.98 ± 0.37 mm; P < 0.002), and 1000 µLPBS (3.28 ± 0.57 mm; P < 
0.0002). Furthermore, the mean distension of the SCS from injection with 500 µL PBS (2.57 ± 
0.52 mm) was significantly lower than the mean distension created from 1000 µL PBS (P < 0.036; 
ANOVA with Tukey’s HSD; Fig. 3). There were no significant differences in distension of the SCS 
between canine and porcine eyes at any injection volume except 800 µL, at which the distance 
was significantly greater in the porcine eye (2.98 ± 0.37 mm) than in the canine eye (2.25 ± 0.21 
mm; P < 0.035; Student’s t-test; Fig. 3).  
 To determine the effect of physiologic intraocular pressure (IOP) on SCS distension after 
injection and to determine the changes of IOP after SCS injection, this study was repeated in 
porcine ex vivo eyes with IOPs of 15 mm Hg. In these eyes, there was no significant difference in 
mean (± SD) distension of the SCS between (eyes injected with 250 µL (1.65 ± 0.79 mm), 500 µL 
(2.8 ± 0.69 mm), or 800 µL (2.8 ± 0.92 mm; Fig. 3). There also were no significant differences in 
mean distension for each injection volume between eyes with IOPs at 15 mm Hg compared with 
the ex vivo porcine or canine eyes (Fig. 3). However, injections greater than 800 µL could not be 
completed because of resistance to injection from high IOPs. In fact, at maximum distension 
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during the injection of 250 µL, IOPs were transiently (<10 seconds) elevated a mean (± SD) of 
39.3 ± 16.5 mm Hg; during the 500-µL injection, IOP increased a mean (± SD) 189.5 ± 118.1 mm 
Hg; and during the 800-µL injection, IOP increased a mean (± SD) 285.8 ± 42.9 mm Hg. 
 
 
Figure 2. High-frequency ultrasound (50 MHz) images demonstrating the distension of the SCS in 
porcine eyes after injection with 250 µL (A), 500 µL (B), 800 µL (C), and 1000 µL (D) of PBS. Left: 
anterior segment; right: posterior segment. S, sclera; C-R, choroid and retina. 
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Figure 3.    Mean ± SD distension of the  SCS after  injection with  PBS measured using  high-
frequency (50  MHz) ultrasound of ex -vivo porcine  eyes  (porcine; n  = 6), canine eyes  (canine; 
n  = 6), and porcine eyes  with  IOP at 15 mm Hg (porcine at 15 IOP; n  = 4).  (a)  Porcine eyes;  
mean  (± SD) distension of the  SCS from injection with  250  µL PBS was  significantly less than  
the maximum distension created from 800  µL PBS (P  = 0.002) and 1000  µL PBS (P  = 0.0002). 
(b)  Canine eyes;  mean  (± SD) distension of the  SCS from injection with  250  µL PBS was  
significantly less than  the  mean  distension created from 500 µL PBS (P  = 0.02), 800  µL PBS (P  
= 0.02), and  1000  µL PBS (P  = 0.005). (c)  Porcine  eyes;  mean  distension of the  SCS from  
injection with   500  µL PBS was   significantly less  than  the  mean   distension created from 
1000  µL PBS (P  = 0.036). (d) Mean distance was significantly less in the canine eye than in the 
porcine eye for the 800-µL PBS injection volume (P = 0.035; Student’s t-test). There was no 
significant difference in mean distension of the SCS in porcine eyes at 15 mm Hg compared with 
the other ex-vivo eyes at any injection volume. 
 
Two-Dimensional Ultrasound Contrast Imaging of SCS.  
 After the injection of microbubble ultrasound contrast agent into the anterior SCS of 
porcine eyes (n = 4 eyes per volume), contrast was visible initially in the SCS at the injection site 
and then at the opposite ventral anterior SCS and the posterior SCS. This is illustrated in Figure 
4, where contrast enhancement (measured as mean pixel intensity) starts to increase first at the 
injection site, followed by the opposite anterior SCS and the posterior SCS. The overall mean (± 
SD) time after injection for contrast to appear at the opposite and posterior SCS was 7.8 ± 4.6 
and 7.7 ± 4.6 seconds, respectively. This suggests that the contrast flowed in the SCS initially 
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parallel to the limbus in the anterior suprachoroidal space as it extended posteriorly (Fig. 5; 
Supplementary Movie S1,http://www.iovs.org/lookup/suppl/doi:10.1167/iovs.11-7525/-/DC 
Supplemental). Mean (± SD) time to maximum contrast intensity visible in the SCS on the 
ultrasound image was 16.2 ± 4.6 seconds after injection. There were no significant differences 
among 250-, 500-, and 800-µL contrast volumes injected in time after injection to appearance of 
the contrast on the ultrasound image (Table 1). In the sagittal ultrasound section, the 
microbubble contrast agent was visible in a mean 24.0% to 27.2% of the entire SCS when 
injected with 250, 500, or 800 µL microbubble contrast agents (Table 1). There were no 
significant differences in area of the SCS where contrast agent was visible among the three 
volumes injected (P = 0.90) or in mean pixel intensity of contrast medium (P = 0.35; Fig. 6). 
Despite only approximately 25% of the SCS having visible contrast, 10 of 12 eyes (83.3%) 
injected had contrast that reached the posterior pole of the eye (one 250-µL and one 800-µL 
injection did not, but contrast was observed to extend to approximately two thirds of the 
posterior SCS). 
 
 
 
17 
 
 
Figure 4.  Mean pixel intensity representing contrast medium enhancement in regions of 
interest placed over the injection site, opposite the anterior SCS and the posterior SCS after 
injection of 250, 500, and 800 µL microbubble contrast agent into the superoanterior SCS of an 
ex-vivo porcine eye.  Measurements of all contrast medium doses are combined in this graph. 
Contrast enhancement increases rapidly at the injection site, followed by the opposite anterior 
and posterior SCS. 
 
Volume of 
Ultrasound 
Contrast 
Injected 
Time to 
Opposite 
Anterior SCS 
(s) 
Time to 
Posterior SCS 
(s) 
Distribution of 
SCS (%) 
Extension to 
Posterior Pole 
250 µL 12.3 ± 5.9 4.3 ± 1.5 24.0 ± 9.3 eyes 
500 µL 6.0 ± 4.1 9.5 ± 6.0 24.6 ± 9.2  eyes 
800 µL 6.3 ± 2.1 8.5 ± 3.9 27.2 ± 13.2 eyes 
Overall 7.8 ± 4.6 7.7 ± 4.6 25.3 ± 9.8 eyes 
Values are mean +/- SD. 
Table 1.  Two-Dimensional Ultrasound Evaluation of the SCS Using Microbubble Contrast 
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Three-Dimensional Ultrasound Contrast Imaging of SCS.  
 As described for 2D ultrasound imaging, in 3D imaging (n 4 eyes) microbubble contrast 
medium first appeared in the SCS at the injection site, then moved to the opposite side of the 
anterior SCS and into the posterior segment. Contrast agent was uniformly distributed in the 
anterior SCS, and reached the posterior SCS in all eyes (Fig. 7; Supplementary Movie S2, 
http://www.iovs.org/lookup/suppl/doi:10.1167/ iovs.11-7525/-/DCSupplemental). Median 
percentage of contrast agent distribution in the entire SCS was 45.3%, with a range of 39.0% to 
52.1%. 
 
Figure 5. Ultrasound image, with overlay of basic ocular schematic, after injection of 500 µL 
microbubble contrast agent into the superoanterior SCS of an ex-vivo porcine eye.  Contrast was 
visible inititally in the SCS at the injection site (1), then visible at the opposite ventral anterior 
SCS (2) and the posterior SCS (3).  An ultrasound system with contrast imaging capabilities was 
used to image the eye. 
 
Discussion 
 A single injection into the anterior SCS resulted in the distribution of latex to nearly 50% 
of the ocular posterior segment in two large animal species commonly used for retinal research. 
The SCS was demonstrated to be able to expand, in a dose dependent manner, to accommodate 
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various volumes of injected fluid. Physiologic IOP did not affect the distension of the SCS after 
injection, but there was a dose-dependent transient increase in IOP after injection. The clinical 
and pathologic significance of this transient increase in IOP must be further investigated; 
however, injections of 500 and 800 L in eyes with physiologic IOP resulted in acute pressure 
elevations likely sufficient to damage retinal ganglion cells or the optic nerve.49,50 The results of 
this study also demonstrated that it is possible to image the SCS with an ultrasound contrast 
agent. Furthermore, these results support our hypothesis that a single anterior suprachoroidal 
injection of a drug with a volume as low as 250 L can reach the ocular posterior segment in eyes 
that approximate the size and volume of the human eye. Together our results suggest that 
injections of 250 L or less can be accommodated by the SCS, result in only transient relatively 
modest elevations of IOP, and rapidly extend to a large percentage of the ocular posterior 
segment. Therefore, further development of SCS injections for treatment of macular disease and 
other diseases of the posterior segment of the eye is warranted.  
 Our results are similar to the results from a recent study of the injection of particles into 
the SCS of ex-vivo rabbit eyes. Using specific microneedles, a 15-L volume of microparticles 
injected into the anterior SCS resulted in distribution of the particles to approximately 36% of 
the total circumference of the eye.51 However, in porcine ex-vivo eyes, 35 L barium sulfate 
contrast agent particles resulted in only approximately 7% posterior segment distribution, as 
determined with reconstructed MRI images.22 Therefore, higher SCS injection volumes, as used 
in our studies, may be required for adequate posterior distribution of medication in larger eyes. 
What effect these large injection volumes had on the in-vivo eye remains to be determined. 
However, it has been demonstrated that the in-vivo rabbit eye can accommodate SCS injections 
of up to 200 L sodium hyaluronate or perfluorocarbon gases.52,53 Therefore, it is likely that the 
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larger canine, porcine, or human eye would also tolerate SCS injection volumes capable of large 
(200–250 L) posterior segment distribution.  
 This study demonstrates that contrast-enhanced ultrasound can be used to determine 
the dynamic distribution of a single anterior SCS injection in real time. Ultrasound contrast 
agents are composed of a perfluorocarbon gas core encapsulated by a lipid shell, stabilized by a 
layer of polyethylene glycol. The microbubbles are suspended in saline at a concentration of 
approximately 1 × 109 particles/mL, with a median bubble diameter of approximately 2.5 µm.25 
Ultrasound contrast agents may not accurately reflect the flow and distribution of drugs in the 
SCS because of differences in particle size and viscosity. Microbubbles, because of their gas 
content, tend to rise to the upper portion of a fluid-filled space, which could alter the 
distribution of the contrast agent in the SCS when compared with injected medication. 
However, the porcine eyes in this study were imaged with the anterior SCS facing up, which 
might have led to an increased accumulation of microbubbles in the anterior SCS and a non–
gravity-dependent liquid would be expected to reach the posterior SCS even better. The fact 
that the ultrasound contrast agent consistently reached the posterior segment is very 
encouraging for the development of SCS injections for the treatment of ocular posterior 
segment diseases.  
 Contrast flow, when observed dynamically in a midsagittal image plane, extended from 
the injection site in the anterior SCS to the contralateral anterior SCS, indicating flow parallel to 
the limbus in the anterior SCS. Simultaneously, or in some eyes with a small delay, contrast 
medium also extended to the posterior SCS. In all eyes the posterior segment was reached by 
the contrast agent within seconds, confirming that the SCS can be used as a site for drug 
delivery and that injections of medications into the anterior SCS, the most accessible location of 
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the SCS, will allow distribution of the drug to the posterior targeted tissue. Viscous or 
microparticle formulations may have different distribution characteristics, but our preliminary 
studies with latex, PBS, and ultrasound contrast demonstrated rapid distribution into the 
posterior SCS.  
 The ability of ultrasound contrast agents to reach the posterior segment of the eye is 
not only of value when considering the anterior SCS as a site for therapeutic drug 
administration, it may also be a method for specific drug delivery. Contrast ultrasound-assisted 
drug delivery has been shown to be feasible both in-vivo and in-vitro.55 Binding of 
pharmaceutical agents to the microbubble shell turns the contrast agent into a vehicle for drug 
or gene delivery.56,56 Moreover, a higher energy ultrasound beam can be applied focally in the 
targeted region, such as the macula, to disrupt microbubbles and cell membranes and locally 
deliver the drug or gene, thus avoiding the systemic distribution of the substance and 
potentially reducing the blood-ocular barrier.14,58  
 Three-dimensional contrast-enhanced ultrasound is a novel technology that allows 
understanding of the pattern of distribution  
 
Figure 6. Mean pixel intensity representing contrast medium enhancement in regions of interest 
placed over the posterior SCS after the injection of 250, 500, and 800 L microbubble contrast 
agent into the superoanterior SCS of an ex-vivo porcine eye. No significant differences in contrast 
medium enhancement were detected with different doses (P = 0.35). 
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Figure 7. Three-dimensional model of contrast agent distribution within the eye. Microbubble 
contrast agent (250 L) was injected into the superoanterior SCS of an ex-vivo porcine eye, and 3D 
ultrasound was performed. The contrast agent in the SCS is isolated in this image; no other 
structures are displayed. The corneal surface faces up in this image. Arrow: injection site. 
 
of contrast medium in the SCS. Selecting a single two dimensional image, or even multiple two-
dimensional images, for measuring the percentage distribution of contrast agent is prone to 
underestimation or overestimation of the actual distribution because of the variability of 
contrast flow within the SCS.59 This may explain the higher percentage of contrast medium 
distribution when considering 3D imaging of the entire eye compared to a single slice; 3D 
imaging was limited to the lowest volume of 250 L because no statistically significant differences 
in contrast distribution were detected with 2D imaging performed with different volumes.  
 These studies represent a novel approach for performing and assessing injections into 
the anterior SCS and suggest that access to the anterior SCS, either by cannula or microneedles, 
may allow the distribution of drugs to a large area of the ocular posterior segment and to the 
macular area of the eye. Additional studies are needed to determine the effect of choroidal  
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blood flow and IOP on the distribution of specific medications and formulations to the retina 
and macula. Furthermore, contrast ultrasound-assisted drug delivery from SCS injections may 
represent a novel, targeted, and less invasive method of treatment of ocular posterior segment 
disease. 
 
 
 
 
 
 
 
CHAPTER 2. 
Effect of acoustic radiation force on distribution of fluorescent dye after injection into the 
anterior suprachoroidal space in ex vivo Eyes 
 
Introduction 
  Microbubble contrast agents (MCAs) are widely used for enhancing blood flow 
imaging in diagnostic ultrasound,36 and are the target of investigation for a wide number of 
uses in therapeutic applications.11,13,16-17 These contrast agents are micron-sized gas filled 
bubbles, typically encapsulated in a stabilizing shell of phospholipid, protein or polymer.3  
The inner core is filled with a high molecular weight or low solubility gas such as 
perfluorocarbons or sulfahexafluoride,36 though cheaper gasses such as nitrogen can be 
used at the cost of decreased stability.  During in vivo use, MCAs are introduced to the blood 
stream, typically through a peripheral venous injection, and circulate within the vascular 
network.  Due to their size, they remain confined to the vascular space and are not able to 
diffuse across the endothelial layer.3 Because of the large acoustic impedance mismatch 
between tissue (including blood) and the gas core of the bubbles, MCAs reflect a significant 
amount of energy back toward the imaging probe. The non-linear response of MCAs during 
acoustic oscillation enable the application of specific imaging strategies to suppress signal 
from tissue which enhances imaging of the vascular space.5 
 In the presence of an ultrasound field, MCAs experience a net force in the direction 
of wave propagation, which will cause displacement of the bubbles.22  Additionally, groups 
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of bubbles experience a net attractive force under the same conditions.23  These effects 
have been termed primary acoustic radiation force (ARF) and secondary ARF respectively.   
This phenomenon has been shown to increase MCA concentration in vivo.  While the overall 
force is small, it is enough to displace MCAs out of the central blood flow in a high flow 
velocity vessel.  It has been shown that the ARF strength is dependent upon both bubble 
size and frequency of the insonifying wave.60 Radiation force is maximized when the 
frequency of the ultrasonic wave matches the resonant frequency of the MCA.60 Bubble 
disruption and destruction occur when an ultrasonic pulse of sufficient pressure is applied to 
the bubble.  Large oscillations of the bubble allow rupturing of the encapsulating shell and 
diffusion of gas into the surrounding liquid causing the loss of echogenicity.3   
 To facilitate both diagnostic and therapeutic applications, MCAs have been designed 
to carry markers or other drugs within or on their surface.13-15  Attaching ligands or 
antibodies to the surface of MCAs allow them to specifically target diseased tissues or other 
areas of interest.18,19  Drugs may be directly incorporated into the shell13 or interior of 
MCAs26, or conjugated to the shell as nanoparticles.14  Destruction of MCAs at specific sites 
within the body can thus result in the targeted release of these therapeutic molecules.   
The majority of current ultrasound transducers provide imaging information in a two 
dimensional plane.  While there are transducers available that provide full three 
dimensional (3D) volumetric data, they are not wide spread and have limited functionality 
for contrast specific applications.  Traditional probes can be used to capture volumetric data 
sets by acquiring multiple images through a volume in a series of parallel slices.18 
Mechanical scanning is the most repeatable way to fully interrogate a 3D sample of tissue 
using a linear array.59 
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 Diseases occurring in the posterior portion of the eye are a leading cause of 
blindness.  These include diabetic macular edema, proliferative vitreoretinopathy, age-
related macular degeneration and endophthalmitis.  While many advancements have been 
made in treating these diseases, delivering drugs to the affected regions remains a 
challenge.  Topical treatments, such as eye drops, often fail to reach the posterior 
segment.28 Intravitreal and subretinal injections provide the ability to overcome this 
limitation but are associated with complications including injection site hemorrhage, retinal 
detachment, the formation of cataracts, elevated intraocular pressure and opacities of the 
visual axis.30-32 The suprachoroidal space (SCS) offers a possible alternative for delivering 
drugs to posterior portions of the eye.  The SCS is a virtual space between the sclera and 
choroid which previous studies have shown allows access from the anterior segment to the 
posterior segment of the eye.  Drugs injected into the SCS avoid the barrier of the sclera and 
can potentially reach targets throughout the globe and may avoid complications associated 
with more invasive injection techniques. Use of the SCS for drug delivery first described by 
Einmahl et al.,34 and the technique has since been used by a number of researchers.40,41,44 
 The goal of the current study is to determine if the application of ARF to 
microbubbles injected into the SCS will increase the posterior localization of a fluorescent 
dye. 
Methods 
3D ultrasound using linear motion stage 
 To perform 3D ultrasound using a linear array ultrasound probe, a linear motion 
stage from Newport (UTS150PP - Newport, Irvine, CA) was used.  The motion stage was 
controlled using a motion controller (SMC100 – Newport, Irvine, CA).  The motion stage and 
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controllers were interfaced to a PC using LabVIEW software (National Instruments, Austin, 
TX).  Using this equipment, the ultrasound transducer could be scanned in a controlled 
fashion along the elevational dimension to fully sample a 3D volume.  
 
Ultrasound System 
 A Mylab 70XVG with LA 332E transducer (Biosound Esaote North America – 
Indianapolis, IN) was used for all experiments.  The system and transducer include a contrast 
specific imaging mode which was used for all ultrasound data acquisition.  The built-in 
“Burst” sequence was used for MCA destruction.  Since the ultrasound system used for this 
study does not have a built in ARF mode, it was required to determine what existing mode 
would provide the best parameters for producing ARF.  Continuous Wave (CW) was chosen, 
because it would best approximate the large number of cycles needed to produce 
translation of the MCAs.  To examine the output of the system in this mode, a needle 
hydrophone (HNA 0200 – Onda, Sunnyvale, CA) was positioned in a water bath with the 
transducer and the pressure output monitored with a digital oscilloscope.  CW parameters 
including power, depth, pulse repetition frequency (PRF) and gate size were all varied in 
order to maximize the number of cycles output.  For application of ARF to eyes the gate size 
was set to 24 mm and placed in the far field, the PRF set to 15 KHz and the frequency set to 
6.3 MHz. 
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Formation of MCAs 
 MCAs were formulated with a lipid solution in a 9:1 molar ratio as previously 
described.61  To create fluorescent MCAs, DiI (Vybrant DiI, Invitrogen - Eugene, OR) was 
incorporated at a concentration of 2 µL per 1.5 mL of lipid solution and stirred using a vortex 
mixer.  The lipid solution was then mechanically agitated for 45 s.  After agitation, MCAs 
were diluted into 10 mL of phosphate buffered saline (PBS) and washed via centrifugation (5 
mins at 3000 rpm) to separate any dye which was not incorporated into the lipid shell of 
MCAs.   The MCAs concentrated after centrifugation were diluted into 4 mL of PBS for a final 
concentration of approximately 7 × 109 bubbles/mL. 
 
Suprachoroidal injections and Imaging 
 Ex-vivo adult pig eyes were collected (NCSU DVM - Raleigh, NC) and trimmed of 
excess adnexal tissue.  Injections into the anterior portion of the SCS were made using 
microneedles (Clearside Biomedical – Atlanta, GA) designed to penetrate through the sclera 
without puncturing into the choroid.  Each globe was injected with 150 µL of MCAs before 
ultrasound imaging began. 
 Eyes were covered in ultrasonic gel to allow acoustic coupling to the ultrasound 
transducer.  A baseline 3D elevational scan was performed in contrast mode to observe the 
distribution of contrast medium after injection.  The ultrasound system was then set to CW 
mode in order to deliver ARF and 3 elevational scans were taken across the eye to apply 
ARF, with the transducer moved laterally between each scan.  After ARF was applied, a 
second contrast scan was taken to observe the distribution of contrast agents after 
application of ARF.  Next, a slow scan across the eye was initiated with the ultrasound 
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system in “Burst” mode to destroy MCAs within the globe.  Finally, a background elevational 
scan was taken to allow subtraction of any nonlinear signal that was present in the absence 
of contrast agents.  Ultrasound data was exported from the system as AVI videos and 
analyzed offline using Image J (NIH- Bethesda) and Matlab (Mathworks - Natick, MA).  
Regions of interest (ROIs) were applied to the 3D ultrasonic data to separate the anterior, 
central and posterior portions of the eye.  The total ultrasound intensity in each region was 
measured before and after application of ARF (Figure 9). 
 
Dissection of eyes and DiI measurements 
 Eyes were set aside for 5 minutes to allow DiI to move throughout tissue, they were 
then frozen on dry ice before being dissected.  Eyes were kept frozen during dissection with 
a cooled ceramic tile above dry ice and 2-methylbutane.  The eye was first divided into 3 
parts via 2 cuts along the coronal plane: an anterior section including the lens, a midsection 
and a posterior section.  Each of these sections was then separated by tissue type into 
vitreous, retina, choroid, and sclera.  To prevent transfer of DiI between samples, the 
surgical instruments were rinsed using PBS followed by methanol followed by PBS and then 
blotted dry.  Samples were stored at -80°C until fluorescence measurements were made. 
 The ocular tissues were added to 0.5 mL of isopropanol (Acros organic - Fairlawn, 
NJ) and shaken with an orbital shaker (Fisher Scientific – Suwanee, GA) for 15 minutes.  The 
aqueous layer was separated out by centrifuging the sample for 10 minutes at 10,000 g.  The 
supernatant was analyzed using a spectrofluorometer (Flouroskan Ascent Fl, 
Thermolabsystem - Helsinki, Finland) using an excitation wavelength of 530 nm and an 
emission wavelength of 590 nm.  A standard solution of DiI with a concentration range of 5 
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ng/mL to 3 µg/mL was prepared in isopropanol to calibrate the system.  Student’s T-tests 
were used to compare results from each section using Excel (Microsoft – Redmond, WA). 
 
Results 
Radiation Force Output 
 The Esaote system was not able to deliver an ideal pulse for ARF within the 
parameter ranges tested.  At the most effective setting of 6.3 MHz, the largest duty cycle 
output was 5% at 17.5 KHz and the ultrasound beam was narrowly focused to a -6 dB width 
of approximately 5 mm.  Though the translational speed of MCAs was not directly measured 
under these settings, previous studies using similar parameters23,24 indicated that bubble 
velocities of 1 mm/s should be expected .   
 
Distribution of contrast agents after ARF 
 3D ultrasound images of contrast medium in the eye both before and after the 
application of ARF by the Esaote system showed no effect on distribution.  Overall there was 
a slight reduction in contrast signal after application of ARF.  This is most likely due to some 
destruction of MCAs during the application of ARF as the pressure in the center of the beam 
(2.4 MPa, MI = 0.95) was high enough to destroy small MCAs.   
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Figure 8. Ultrasound contrast image from central slice of eye showing the three ROIs used: 
anterior (top) center (middle) and posterior (bottom) before and after application of ARF.  
A) Before application of ARF.  B) After application of ARF 
 
 
Figure 9. Ultrasound image intensity for each ROI in the eye, before and after application of 
ARF (n = 6).  Images were collected across the entire 3D volume of the globes and ROIs 
applied for each captured image slice.  Data shown are the summed ultrasound intensity 
across each ROI for the entire 3D volume. 
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Distribution of DiI with and without ARF 
 Measurements of DiI concentration within the various tissues showed highly 
variable results.  In 54.5% of tissue samples, the concentration of DiI was below the 
measurement threshold of the spectrofluorometer.  In the remaining samples, the 
concentrations ranged from 2 to 275 ng/g tissue.  The total concentration of dye detected in 
each eye varied from 110.9 to 712.3 ng/g (average 281.3, stdev 139.5).  This variation in 
concentration could not be accounted for by differences in eye mass. 
The measured concentration of DiI in each tissue section is provided below. 
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Vit Ret Cho Scle 
1 ANT 0 0 62.5 176 
1 MID 2.6 15 116 10.2 
1 POST  25 20 275 10 
2 ANT 2.27 0 40 16.6 
2 MID 2.6 0 75 40 
 2 POST  0 0 50 2.89 
3ANT 0 66 150 15.62 
3 MID 0 0 0 18 
 3 POST  0 0 0 3.12 
4 ANT 3.96 0 200 28.12 
4 MID 3.26 0 100 18.5 
4 POST  16.6 27.2 125 4.3 
5 ANT 11.8 0 66.66 25.8 
5 MID 3.9 0 83.3 36.36 
 5POST  5 27.7 100 5.9 
6 ANT 6.75 0 116.6 37.5 
6 MID 0 27.7 125 28.5 
  6 POST  5.43 0 0 7.5 
7 ANT 0 0 0 18.5 
7 MID 7.6 108 83 20.8 
7 POST  13 0 0 6.5 
8 ANT 0 0 66.5 28 
8 MID 0 0 0 30.9 
 8 POST  0 33 0 5.4 
9 ANT 0 111 50 21.8 
9 MID 0 0 0 26 
 9 POST  0 0 0 5.71 
10 ANT 0 87 58 21 
10 MID 0 0 0 33.3 
10 POST  54.4 0 0 4.5 
11 ANT 0 0 66.66 25 
11 MID 0 0 0 31.5 
 11 POST  0 0 0 6.25 
12 ANT 0 0 112.5 39.4 
12 MID 0 0 0 28.9 
 12 POST  0 0 0 5.22 
Table 2.  DiI concentrations measured by spectrofluorometry for 4 tissue types in the ARF 
treated eyes, units of ng DiI/g tissue.   
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  Vitreous Retina Choroid Sclera 
7 ANT 3.03 0 100 35 
7 MID 2.06 0 0 16.1 
7 POST  1 0 0 3.73 
8 ANT 3.4 0 66 29 
8MID 0 0 0 7.8 
 8POST  0 0 0 4.7 
9ANT 2.22 0 87.5 31.25 
9 MID 2.5 35 0 48.6 
 9 POST  0 0 0 3.42 
10 ANT 3.9 0 62.5 31.25 
10 MID 0 0 75 30.5 
10 POST  0 0 1 4.22 
7 ANT 0 0 70 28.2 
7 MID 0 0 0 39.47 
7 POST  0 22 83 6.3 
8 ANT 0 0 
 
55 
8MID 0 0 100 40 
 8POST  0 0 0 5.7 
9ANT 4.25 0 58 38 
9 MID 0 0 125 50 
 9 POST  0 0 62.5 9.18 
10 ANT 0 0 112.5 38 
10 MID 0 0 175 4.11 
10 POST  0 0 100 8.69 
11 ANT 0 41.6 90 50 
11 MID 0 0 50 26 
11 POST  0 0 83 5.76 
12 ANT 0 0 75 40 
12 MID 0 0 0 22 
12 POST  0 0 100 30 
Table 3.  DiI concentrations measured by spectrofluorometry for 4 tissue types in the 
control eyes, units of ng DiI/g tissue.   
 
 Use of radiation force did not produce any changes in the relative distribution of 
fluorescence signal in the anterior portion of the eye compared to the entire eye (p = 0.74) 
or the posterior portion of the eye versus the whole eye (p = 0.89) as seen in Figure 10. 
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Figure 10.  Percent of DiI residing in each region of the eye as compared to the whole eye 
for controls (n = 10) and ARF treated (n = 12).  Most dye was concentrated in the anterior 
portion of the eye was contrast agents were injected.  Treatment with ARF had no effect on 
dye distribution. 
 
 Analysis showed that significantly more dye resided in the choroid and sclera than 
the vitreous and retina.  Since both choroid and sclera are adjacent to the SCS this finding is 
consistent with the physical layout of the eye.  Concentrations were next highest in the 
retina, which can be reached by passing through the choroid.  Concentrations in the vitreous 
were the lowest. 
 There was a statistically significant difference in the concentration of dye in the 
retina (p = 0.04) and in the vitreous (p = 0.03) between the ARF treated group (n = 12) and 
the control group (n = 10).  No such difference existed in concentrations for the choroid and 
sclera (Figure 11). 
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Figure 11.  Concentrations of DiI in each anatomical tissue ng of DiI/gram of tissue for control 
eyes (n = 10) and ARF treated eyes (n = 12).  Treatment with ARF caused significantly increased 
concentrations in the vitreous (p = 0.03) and in the retina (p = 0.04). 
 
Discussion and future work 
Acoustic radiation force parameters 
 Because the ARF beam used on the Esaote machine was much more tightly focused 
than the size of an eye, it was difficult to achieve a balanced intensity that was not 
destructive but was effective for pushing.  The compromise reached was to lower the center 
pressure; however, this required that the transducer be scanned across the eye multiple 
times in order to generate a reasonable amount of radiation force across the entire volume 
of the eye.  In an in-vivo setting this would be disadvantageous as it increased the overall 
treatment time by a factor of 3.  A brief follow up study (n = 3) was conducted using an 
Acuson Sequoia system  (described in Chapter 1) which has proven effective for delivering 
ARF.24  Briefly, the ARF was achieved using a 7 MHz pulse at 28 kPa with a PRF of 25 kHz. 
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These preliminary results indicated that even with an effective ARF pulse,  no movement of 
MCAs toward the posterior of the eyes was achieved.  Possible reasons for the failure of ARF 
to move contrast medium is discussed below. 
 
Effects contributing to MCA distribution 
 The majority of imaged eyes contained two distinct regions where MCAs accumulated, 
around the lens and in the rear of the eye.  Significantly less contrast medium was seen along 
the sides of the globes.  The geometry of the SCS may be responsible for this bimodal 
distribution, or other factors may be at work.  Because MCAs are gas filled, they experience a 
buoyancy force; therefore the orientation of the eyes to gravity will play a role in MCA 
distribution.  All eyes for this study were imaged with the lens facing up.  For in-vivo applications 
this orientation may be difficult or impossible to achieve depending on the species under 
investigation.  It therefore is important to ascertain the effect of eye orientation on the 
distribution of MCAs. From the ultrasound images collected, there was no evidence that the ARF 
parameters used in this study were effective at altering the distribution of contrast agents 
within the eye.  It is possible that between the application of ARF and the subsequent imaging, 
MCA buoyancy could have undone the effect of ARF.  This however seems unlikely as the drag 
forces on small MCAs mean that their rise through a liquid column is relatively slow. 
 An additional factor affecting MCA distribution is external and internal pressure.  Eyes 
for this study were fully separated from the rest of the head anatomy and freely seated in 
ultrasound gel, and care was taken to avoid applying pressure to the globes with the transducer.  
The effect of pressure, both from the transducer and from the eye socket, may alter the shape 
and distension of the SCS.  Internal pressure from expansion of the SCS itself was evident, as 
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after injection of MCAs, small amounts were clearly visible exiting from the injection site.  The 
spherical nature of the SCS is likely to diminish the effectiveness of ARF application.  The 
curvature of the eye means that only in a small region is all of the energy from ARF parallel to a 
direction which a bubble can actual follow.  Near the top of the eye, where much of the contrast 
agents collects via floatation, most of the energy is normal to the outer layer of the choroid, 
rather than tangential to it.  As a result, bubbles were likely forced against the choroid instead of 
forced to move along it. 
 Finally, while it seems most likely that the application of ARF had little effect on 
distribution of MCAs, it is possible that any effect was hidden due to saturation of the 
ultrasound images.  As a result, any additional contrast agents entering saturated regions of 
the images would not be detectable in images.  Adjustment of gain and dynamic 
compression of the images should be adjusted to prevent saturation from occurring. 
 
Effects contributing to drug distribution 
 The DiI concentrations as measured by spectrofluorometry also showed no effect in 
increasing concentration toward the rear of the eye.  However, concentrations of DiI in the 
retina and vitreous did increase with application of ARF.  To reach these tissues, DiI needs to 
pass through the choroid.  It was beyond the scope of this study to ascertain if this occurred 
while still incorporated into a microbubble shell or, more likely, if it occurred after microbubble 
destruction.  Cellular permeability and sonoporation could be increased in ARF treated eyes, due 
to the greater amount of ultrasound energy applied.  This is a possible explanation for the 
increase in DiI concentration in the retina and vitreous for the treated eyes. 
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 The dye used in this study, DiI, is a fluorescently labeled lipid.  Different marker 
molecules or actual drug molecules will have different diffusion properties and would likely 
distribute throughout the eye tissues in different ways.  SCS treatments in an in vivo eye face the 
additional diffusion barrier of the choroidal circulation.  In order to cross from the SCS into the 
retina, drugs need to avoid being washed out or diluted by this barrier.  Testing of ex vivo eyes 
which are artificially perfused with saline or a blood substitute will help elucidate the effect on 
therapeutic dose delivered to the retina.   
 
Other injection techniques 
 Research by Park et al.11 has shown that microbubbles may be used to disrupt the retina 
blood barrier.  This may prove a more effective method for delivering drugs to the retina than 
ocular injection.  A comparison of the effectiveness of this technique with ocular injection is 
warranted.  However, this would require in-vivo experiments since effects of blood flow and 
tissue perfusion would have significant effects on the outcome.  
 
Clearance of MCAs from the SCS 
 In the blood stream, MCAs are cleared by diffusion of gas from the core into the 
bloodstream,62 and by immune responses;63 however, the clearance rates and mechanisms have 
not yet been studied in the SCS.  In the present study, MCAs were fragmented using destructive 
ultrasound pulses, but it is not guaranteed that all MCAs could be fragmented during an in vivo 
study. 
 
 
 
 
CHAPTER 3.   
Controllable microfluidic synthesis of multiphase drug-carrying 
lipospheres for site-targeted therapy‡ 
 
 
Introduction 
 
Recent advances in molecular biology and genetic research have made possible the 
creation of more powerful and effective cancer therapeutics, bringing about the realization 
of the century-old concept of ‘‘magic bullets’’ that can carry therapeutic drugs to target sites 
with high specificity.64 Efficient carrier-based systems are of increasing importance because 
of the growing number of active pharmaceutical ingredients (API) with low bioavailability.65 
One of the biggest limitations with current cancer therapy with chemotherapeutics has been 
the systemic toxicity involved, especially with the intravenous or oral administration route. 
A lack of selectivity to tumor tissues impedes the therapeutic potential of anticancer 
drugs.66 Advances in chemotherapeutics include encapsulating these cytotoxic drugs in a 
liposome to minimize systemic effects.67,68 Liposomes consist of single or multiple concentric 
lipid layers (lamellae) that encapsulate an inner aqueous core. Hydrophilic drugs can be 
carried in the aqueous compartment of a liposome, and hydrophobic drugs can be 
incorporated in the lipid bilayer. Polymers such as polyethylene glycol (PEG) can be attached 
to the surface for stabilization and increase liposome residence time in the blood  
 
_____________________________ 
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circulation, and particular ligands such as antibodies or peptides can be attached to increase 
specificity for target sites.69 By tailoring the size, material characteristics, or shell 
components of the liposome, researchers have been able to achieve some specificity of 
where these vehicles accumulate, preferentially in tumors.70 Several major FDA-approved 
cytotoxic liposomal formulations (e.g. DaunoXome®  , DepoCyt® , Doxil®  , and Myocet®  ) 
have been in the market since the 1990s. Liposome-based products however suffer from 
relatively nonspecific biodistribution after injection. Accumulation of liposomes by size 
selection or molecular targeting is a slow process.71 It is desirable to minimize nonspecific 
drug carrier accumulation because of the toxicity involved with most chemotherapeutic 
agents.  
Although an API can passively diffuse into a liposome, encapsulation yields are often 
small, especially when the API possesses some degree of membrane permeability. Active 
encapsulation methods involving, for example, a gradient in pH or chemical potential72 have 
improved yields, but release of the API in a controlled manner is often a challenge. Release 
mechanisms range from passive means such as liposome disintegration or diffusion-driven 
leakage to more active release methods triggered by external or environmental stimuli such 
as a change in pH, temperature, or enzymatic degradation.73–75 Regardless of a passive or 
active mechanism, an unpredictable release profile will lead to a lack of control in drug 
release.  
One method that has shown initial promise for controlling particle localization and 
disruption is ultrasound.14 Standard liposomes are not acoustically active because their 
density and compressibility are similar to the surrounding blood. Microbubble carriers are 
uniquely suited for ultrasound enhanced local drug delivery because they can be selectively 
concentrated and disrupted at the region of the acoustic focus.60 Additionally, the rapid 
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mechanical oscillation of microbubbles in an acoustic field has been shown to enhance the 
delivery of compounds across cell membranes76 as well as result in local increases in 
vascular permeability.77,78 These stabilized gas microbubbles are used in the clinic today as 
ultrasound contrast agents to enhance the reflectivity of perfused tissues in applications 
spanning cardiology79 and radiology.80 Although molecularly targeted agents have not yet 
been applied clinically, preliminary studies have demonstrated application in vascular 
inflammation and angiogenesis, where researchers have shown the effectiveness of 
targeted lipid microbubbles as a diagnostic tool in detecting tumors and metastatic spread 
by assessing the degree of new blood vessel growth.81–83 However, the thin microbubble 
shell and gas core each have limited drug-carrying capacity. Researchers have recently 
created a new drug delivery vehicle by mounting the liposomes on microbubble shells.15 This 
new vehicle possesses the drug payload capacity of liposomes yet can still be concentrated 
with ultrasound radiation force and disrupted with the higher energy acoustic pulses.  
The utilization of multilayer gas lipospheres capable of delivering bioactive 
substances at high concentrations is an interesting prospect for the development of cancer 
treatments. 26 As shown in Figure 13, such lipospheres possess a layer with drug-carrying 
capacity (such as oil) and a gas core with significantly different density and compressibility 
than the surrounding liquid media, providing contrast for ultrasound imaging. These vehicles 
can be steered, concentrated, and disrupted with ultrasound, both in-vitro and in ex-vivo 
microvasculature.84 Gas lipospheres however are challenging to produce in a controlled 
manner because of current manufacturing processes. Conventional production techniques 
involve the use of mechanical agitation85 or sonication86, both of which create a highly 
polydisperse population. Thus, the drug dosages within each vehicle are also not consistent, 
and microscopy often shows a percentage of vehicles without any gas at all, leaving them 
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acoustically inactive. The size distribution of the vehicle is extremely important because 
parameters such as the destruction threshold, amount of radiation force experienced, 
resonant frequency (important for imaging), and biodistribution are significantly affected by 
the vehicle diameter.60,87,88  
 
 
 
Figure 12. Schematic of a multilayer gas liposphere with targeting capability, carrying 
therapeutics in the lipid-oil complex.  
 
To control particle synthesis and drug encapsulation, our manufacturing strategy 
utilizes microfluidics technology. The versatility in function and application of the 
microfluidic platform has provided unique solutions to healthcare problems within a span of 
just a few years.89–94 Microfluidics is one of the few technologies that is able to produce fluid 
emulsions with high precision.95 Microfluidic techniques have already shown to be powerful 
technologies for the generation of highly controlled droplet dispersions96–99 and 
microbubbles.100-103 An additional major advantage of microfluidics is that the potential also 
exists for manipulating the chemistry and material characteristics of droplets or particles 
44 
 
within the devices so that different functional properties are added for a given application. 
Using microfluidic flow-focusing, we recently demonstrated the production of lipid-based 
microbubbles with a much narrower size distribution than commercially available for use as 
ultrasound contrast imaging agents.103 A monodisperse microbubble population leads to a 
more consistent echo response and the potential for higher sensitivity in molecular imaging.  
In this work, we report the ability to generate functionalized multilayer gas 
lipospheres with precisely controlled size and drug carrying capacity. Previous works in the 
literature have demonstrated the application of multilayer lipospheres as drug delivery 
agents, but those vehicles were produced with techniques that resulted in size and loading 
inconsistency. This is the first such article that describes a system for providing a high level 
of manufacturing control in the production of these complex (three-phase) biocompatible 
particles. Our microfluidic device in Figure 14 combines two hydrodynamic flow-focusing 
regions together and features expanding nozzle geometry to generate monodisperse 
gasfilled lipospheres. The same design may be used to generate single or multilayer gas 
lipospheres.  
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Figure 13. Geometry of device for gas liposphere production. (a) Schematic view of the 
microfluidic flow-focusing device. All channels have a rectangular cross section and a height 
of 25 lm. (b) Main functional area with a 25 lm orifice and filtering channels. The arrows 
indicate direction of flow. (c) 3D view of assembled PDMS device on an inverted microscope. 
 
Materials and methods  
Photolithography and fabrication  
Fabrication of devices followed standard soft lithography techniques.104 Briefly, 
fluidic channel geometries were designed in Illustrator (Adobe) and printed at 20,000 dpi 
onto transparency masks by CAD/Art Services (Bandon, OR). In a class 10,000 clean room, a 
3 in. silicon wafer was first oxidized in oxygen plasma for 10 min at 200 W and 100 mTorr 
and then spin-coated at 2,000 rpm with a UVcurable epoxy (SU-8-25, MicroChem) to form a 
25 µm high layer. Exposure to UV light through the photomask containing the channel 
pattern crosslinks the exposed areas of SU-8, which then remain on the wafer after 
development.  
The wafer was used to cast a replica in the silicone elastomer polydimethylsiloxane 
(PDMS) (Sylgard 184, Dow Corning), consisting of a 10:1 prepolymer and curing agent ratio. 
PDMS as a stamp material has favorable properties such as optical transparency and wide 
solvent compatibility. The prepared mixture of PDMS was degassed under vacuum, poured 
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onto the wafer with template, and cured for at least 4 h at 65°C in a temperature-controlled 
dry oven. The cured PDMS was peeled from the wafer in a laminar flow hood. Inlets and 
outlets were punched with a blunt 18 G needle, and the stamp was bonded to clean soda 
lime glass (Corning) after 90 s of air plasma (200 mTorr, 200 W) treatment with an expanded 
air plasma cleaner (Harrick Scientific, NY). To preserve the hydrophilicity of the PDMS after 
plasma preparation, channels were immediately filled with DI water. 
 
Lipid materials and preparation 
The lipid flow stream contains an aqueous glycerol/propylene glycol (GPW) mixture 
from Sigma (St Louis, MO) with the stabilizing lipids DSPC (1,2-distearoyl-sn-glycero-3- 
phosphocholine, Avanti Polar Lipids) and polyethylene glycol (PEG) lipid conjugate DSPE-
PEG2000-Biotin (1,2- distearoyl-sn-glycero-3-phosphoethanolamine-N-
(biotinyl(polyethylene glycol)2000), Avanti Polar Lipids) at a concentration of 0.5 mg mL-1 
DSPC. These lipid shell components are similar to those commonly used for formulation of 
lipidencapsulated ultrasound contrast agents.105 
First, DSPC and DSPE-PEG2000-Biotin were combined at a 9:1 molar ratio and 
dissolved in chloroform (CHCl3, Sigma) to create a homogenous mixture. The solvent was 
evaporated with a nitrogen stream, exposed to vacuum, and allowed to dry. DiI-C18 (1,10-
dilinoleyl-3,3,30,30-tetramethylindocarbocyanine perchlorate, Molecular Probes) was then 
added at 1 mol % for fluorescence microscopy studies of the outer lipid shell layer. Ultra-
pure water was added to the vial containing the dry lipid mixture, sonicated at room 
temperature for 20 min, and combined with glycerol/propylene glycol to form a 10% GPW 
mixture. The solution was again sonicated during preparation and immediately before using 
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at 37°C to prevent unwanted liposome formation. To ensure air saturation, the lipid solution 
was stirred overnight in a 1 atm air environment. 
 
System assembly 
The PDMS microfluidic device was placed on an inverted fluorescence microscope 
(TE2000, Nikon) before external fluidic connections are made. Nitrogen (N2, Airgas) for 
multilayer gas lipospheres or octofluorocyclobutane (C4F8, Specialty Chemical Products) for 
single-layer gas lipospheres were supplied from pressurized tanks via clear TygonVR tubing 
and delivered into the gas inlet of the microfluidic chamber using a homemade micro flow 
meter. The continuous liquid (lipid and oil) phase mixtures in 3 cc Becton-Dickinson syringes 
were pumped into the microfluidic device via 23 G hypodermic tubing at constant flow rates 
using two digitally controlled syringe pumps (Pico Plus, Harvard Apparatus). A high-speed 
camera (Fastcam PCI-10K, Photron) was used to capture monochrome still images and 
record movies. A file viewer (PFV, Photron) and image analysis program (ImageJ, NIH) were 
used for data processing and measurements. The polydispersity index  = δ /davg × 100% 
was calculated from the average vehicle size davg and standard deviation δ, determined by 
measuring the sizes of at least 100 gas lipospheres from recorded images. 
 
Cell culture 
Minimum essential medium (MEM), sodium pyruvate, sodium bicarbonate, 
trypsin/EDTA, gentamicin, and fetal bovine serum (FBS) were obtained from Invitrogen 
(Carlsbad, CA). Phosphate buffered saline (PBS) and collagen type IV were obtained from 
Sigma (St Louis, MO). The human metastatic breast cancer cell line MDA-MB-231 was 
donated and originally purchased from American Type Culture Collection (Manassas, VA).  
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The cells were cultured in MEM supplemented with 10% FBS and sodium pyruvate, 
sodium bicarbonate, gentamicin at 37°C in a 5% CO2 incubator. Cells were grown on cover 
slips coated with collagen type IV (100 µg mL-1) to provide an adherent surface for cells. 
Labeling of the cytoskeleton was performed on live adherent cells in culture plates using 
TubulinTracker Green reagent (T34075) from Invitrogen (Carlsbad, CA). Mitochondria were 
stained with MitoTracker Deep Red 633 (M-22426) from Invitrogen (Carlsbad, CA), and the 
nucleus was stained blue with Hoechst 33342 (H1399) from Invitrogen (Carlsbad, CA). 
Labeling occurred predominately on the exposed surface.  
Biotin (EZ-Link Sulfo-NHS-LC-Biotin, Pierce) binds with high affinity to avidin and was 
used for labeling of cell surface proteins. MDA-MB-231 cells adherent to glass cover slips 
were washed with ice-cold PBS three times to avoid amine-containing components 
competing and quenching the reaction to cell surface proteins. Cells were suspended at a 
concentration of ~25 ×106 cells mL-1 in PBS (pH 8.0) and then incubated in 1.0 mg mL-1 
biotin/PBS solution (results in ~2 mM biotin reagent) for 30 min at room temperature 
before rinsing with a PBS and 100 mM glycine solution. 
 
Imaging and binding 
Gas lipospheres in the form of foam were collected using a glass pipette from the 
outlet reservoir for imaging of the stained lipid membranes. Aliquots were transferred onto 
glass slides and secured with plastic cover slips to reduce fluid flow and contain the 
lipospheres. The sample was positioned on the microscope stage, and detection of 
fluorescence occurred at λ = 569 nm due to DiI labeling.  
For visualization of the inner oil layer, triacetin oil (Glyceryl triacetate, Sigma), 
capable of carrying bioactive substances, was premixed with Oil Blue N dye from Sigma (St 
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Louis, MO) at a concentration of 0.01 mg mL-1. The viscosity of triacetin (28.0 cP) is 
considerably less compared with other oils, making it ideal for use at the desired liquid flow 
rate regimes of 0.25–0.50 µL s-1 in the microchannels. Doxorubicin (Dox) from Sigma (St 
Louis, MO) was used as the model antitumor drug because of the intrinsic fluorescence 
properties of the molecule. Dox was mixed with triacetin at a concentration of 1 mmol L-1. 
Drug concentration of Dox (ex λ = 470 nm; em λ = 585 nm) within the oil layer was visualized 
by fluorescence microscopy with rhodamine optics.  
For gas liposphere-cell binding studies, 10 µL of Avidin (ImmunoPure Avidin, Pierce) 
was added to 500µLof biotinylated vehicles. After 5 min, the vehicle solution was washed 
with DI water several times. The mixture was collected with a glass pipette and applied 
directly to the adherent cells on collagen type IV-coated cover slips and imaged with an 
Olympus BX-41 microscope and CytoViva imaging system consisting of a high-resolution 
illuminator, dual mode fluorescence module, and Exfo fluorescence light source. Gentle 
movement of the cover slips was sufficient to achieve some degree of binding between the 
floating gas lipospheres and the adherent cells at the bottom. 
 
Acoustic response 
The acoustic response of 15-lm multilayer gas lipospheres was measured as they 
were pumped at a low concentration through a 200 micron acoustically-translucent tube 
suspended in a water bath on the inverted microscope. Vehicles were excited with a 1 cycle, 
2.25 MHz acoustic pulse at ~200 kPa using a spherically focused ultrasound transducer 
(V305, Panametrics), energized with an arbitrary waveform generator (AWG2021, Tektronix) 
and amplifier (3200L, ENI). The transducer was positioned in the water bath, and the 
acoustic focus was aligned with the translucent tube. Echo signatures for each gas 
50 
 
liposphere were received using a second 2.25 MHz transducer, amplified by 40 dB (BR640, 
Ritec) and then recorded using a 14-bit, 100 MHz digitizer (PDA14, Signatec) through a 
LabView (National Instruments Corporation, Austin, TX) interface. Offline processing in 
Matlab (The Mathworks, Natick, MA) was used to calculate the average correlation between 
echoes. The size distribution of the polydisperse microbubbles used as a control was similar 
to the size distribution of Definity® (Lantheus Medical Imaging, North Billerica, MA), an 
ultrasound contrast agent approved by the US Food and Drug Administration (FDA). 
 
Results and discussion 
Device parameters 
Liposphere size and production rate are highly prone to downstream pressure 
conditions in microfluidic channels. Thus, channel geometry and the liquid and gas flow 
rates are important parameters for stable production and precise control of the liposphere 
sizes. Combining two hydrodynamic flow-focusing geometries together into a single region 
proved less sensitive to gas pressure than in double flowfocusing geometry where the two 
flow-focusing regions are separated by an arbitrary distance. This was critical to the stable 
formation of smaller sized multilayer gas lipospheres. The gas inlet distance from the orifice 
region was minimized to reduce gas diffusion and reduction in the widths of the liquid and 
gas inlet channels to 30 and 20 µm, respectively, enabled the use of lower liquid flow rates 
and gas delivery pressures to generate micron-sized lipospheres. To reduce bubble contact, 
the outlet reservoir immediately followed the expansion chamber. The liposphere volume V 
depends on the ratio of the gas pressure P and overall liquid flow rate Qt, which is a 
combination of the oil and lipid/water flow rates Q0 and Qw. V increases linearly with P for a 
fixed Qt. An increase in Qt results in a decrease in V.  
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For the production of gas lipospheres, a pressure drop must occur along the 
longitudinal axis of the device until the tip of the gas stream breaks at the orifice. We found 
that the most stable production regime occurs when the oil and lipid/ water phase form an 
interface of equal pressure upstream of the orifice. Because of the large viscosity difference 
between triacetin oil and water (28.0 cP vs. 1.0 cP), the oil flow rate Q0 was minimized as 
much as 30-times less in comparison to the lipid/water flow rate Qw. Channels were also 
designed to minimize the contact time and angle between the oil and gas flow streams just 
prior to the orifice. Because PDMS has the characteristics of high-diffusion coefficients to 
gases such as nitrogen, reducing the distance between the gas inlet and orifice results in a 
lower P necessary to produce the same V for a fixed Qt. 
 
Generation and stability 
By simple adjustments in flow parameters, differently sized gas lipospheres were 
produced using the same microfluidic flow-focusing device. The flow condition relationships 
can be found in Figure 15a. Stable production rates of 6 ×104 multilayer gas lipospheres per 
minute have been recorded from a single chamber, requiring several hours to achieve an 
estimated 2 × 107 vehicles necessary for imaging and drug delivery. This relatively slow 
production rate currently limits our microfluidics system for use as a viable bulk 
manufacturing process. The PDMS devices are however robust enough for consistent 
production of gas lipospheres, and runtimes that last more than 6 h have frequently been 
observed. Multiplexing several flow-focusing circuits together will also lead to higher 
throughput and time and cost savings. A 10-fold scale-up of microbubble contrast agent 
production in our lab has been achieved without a significant change in dimensions of the 
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device. We feel that future device design improvements will likely allow for large-scale 
production of these vehicles.  
 
 
Figure 14. Flow rate vs. size relationships. (a) The optimum flow rate regime (highlighted) to 
produce <15 lm multilayer lipospheres, with five different flow condition points (filled 
diamonds) that produce mean liposphere sizes of {11, 7, 17, 22, 30 ± 0.2 µm}, respectively. 
(b) High-speed images showing changes in gas liposphere size upon application of a low 
lipid/water flow rate of 0.33 µL s-1 (left) and a high lipid/water flow rate of 0.5 µL s-1 (right). 
The widths of the liquid, oil, and gas inlet channels are 30 µm, 25 µm, and 20 µm, 
respectively, and the orifice size is 25 µm. (c) Images showing close-up of two multilayer 
lipospheres clearly showing the inner blue oil layer (top) and monodisperse multilayer gas 
lipospheres visible in brightfield (bottom).  
 
As can be seen in Figure 15b, the smaller sized (7.5 ± 0.2 µm) gas lipospheres were 
produced at a lipid/water flow rate of 0.33 µL s-1 and a gas pressure of 1.0 psi, while the 
larger sized (>20 lm) vehicles were produced at a lipid/water flow rate of 0.5 µL s-1  and gas 
pressure of 1.6 psi and higher. The oil flow rate Q0 was set at a constant 0.016 µL s
-1. We 
found that the smaller lipospheres undergo dissolution to a terminal size where the shell 
achieves very low-surface tension as they were rising to the top. These lipospheres remain 
stable over the experimental period of 3 h. Increasing the gas and liquid flow rates however 
decreases the distance between exiting lipospheres. These contact interactions cause them 
to coalesce due to the lower shell resistance in a highflow velocity environment of the 
microfluidic expansion chamber, destroying the desired monodispersity of the bubble 
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population. Growth in size was also seen for many of the larger (>20 lm in diameter) vehicles 
after they reached the outlet reservoir, typical of Ostwald ripening.106 Because the gas 
lipospheres rise to the surface producing a highly concentrated layer known as a cream, 
reducing vehicle size (a function of flow parameters) or increasing the viscosity of the 
continuous lipid/water phase will delay the rise time and creaming. Varying the percentages 
of glycerol/propylene glycol will change the viscosity of the solution, and can therefore be 
used to optimize microbubble stability. With sufficient time, vehicles that reach their 
terminal size form a fully compressed lipid monolayer shell that has reached a near zero 
surface tension.107  
We are currently exploring improved methods of stabilizing these drug delivery 
vehicles. Possible solutions to improve long-term stability may include adding polaxamers, a 
different PEG group, or photopolymerizable lipids. However, it may not be necessary to 
substantially increase shelf life if the vehicles can be manufactured at the point-of-care. 
Clinical (FDA-approved) lipid contrast agents that are formed via mechanical agitation are 
injected immediately into the patient, eliminating the need for long-term stability. Testing 
in-vivo will be necessary to determine circulation lifetime, as the blood pressure and 
dissolved gas concentration may affect stability. 
 
Structure visualization 
The outer DSPC lipid shell stabilizes the vehicle and the inner triacetin oil layer can 
contain dissolved therapeutics. Using a lipid dye, DiI, fluorescence microscopy images of 
these monodisperse vehicles were taken to confirm the lipid coating on the vehicle surface. 
The inner dark blue layer confirms the existence of the additional triacetin oil layer. The 
volume fraction of the oil layer can be adjusted using flow rates for varying the 
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chemotherapeutic drug concentrations. The gas interior makes the vehicle acoustically 
active to ultrasound pulses. Low polydispersity values (<5%) demonstrate the advantage of 
the microfluidic method of manufacture. In contrast, multilayer gas lipospheres capable of 
carrying consistent drug payloads cannot be reliably made with standard mechanical 
agitation techniques. Such lipospheres have high-polydispersity values of >50%.26  
Microfluidic-generated multilayer gas lipospheres are visible in brightfield after 
being collected on the cover glass, as seen in Figure 16a. A 10 µm gas liposphere contains 
~0.5 pL of drug-carrying capacity. Based on an analysis of fluorescence measurements, 
standard curves of Dox dissolved in triacetin were used to estimate the drug content in the 
gas lipospheres. Dox is a naturally fluorescent anthracycline antibiotic and anticancer drug. 
It has been prepared in liposomal formulations as Doxil® and Myocet® to treat kaposi’s 
sarcoma (KS) and metastatic breast cancer. The pattern of Dox fluorescence did not change 
remarkably in the vehicle suspensions after 1 h of monitoring. As seen in Figure 16b, the 
sharp boundary is due to the partitioning of Dox preferentially at the boundary of the 
lipid/oil layer. This is expected as Dox favors the lipid layer, and the drug has not been 
observed to leach out spontaneously. At the 1 mmol L-1 concentration of drug used in this 
study, the total amount of Dox entrapment is estimated at 15 mg mL-1 of packed particles. In 
a dual-layer vehicle, a large volume fraction of the oil phase can be used and other 
chemotherapeutic drugs such as Paclitaxel, which exhibits good solubility in triacetin (70 mg 
mL-1), can be incorporated at high concentrations. At this concentration, ~2.5 mL of 
suspension would be necessary for an average dose in a human patient. Until now, the 
ability to accurately control the amount of drug in each vehicle has not been possible. 
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Figure 15. Microscopy images of multilayer gas lipospheres containing Doxorubicin. (a) 
Brightfield image of lipospheres. Scale bar is 15 lm. (b) Fluorescence image of lipospheres 
showing Dox fluorescence within the lipid-oil complex. Scale bar is 15 µm.  
 
Cell targeting 
To demonstrate the targeted binding of monodisperse gas lipospheres to cancer 
cells and potential for localized chemotherapeutic drug delivery, we functionalized our 
vehicles by incorporating biotinylated lipid into the shell. Many current targeted molecular 
imaging methods involve using the avidin-biotin interaction.108 The avidin-biotin interaction 
is the strongest noncovalent interaction between a protein and ligand. Without the 
conjugation, we have seen that the gas lipospheres will float on the top of the solution and 
will not adhere to the anchored biotinylated cells at the bottom. On collection of the 
functionalized gas lipospheres, it was necessary to perform gentle movement of the cover 
slips to achieve some degree of binding. The live, labeled MDAMB- 231 breast cancer cells 
remained viable for up to 5 days of culturing under constant perfusion of media, but died in 
a matter of hours on cover slips from stress due to experimental conditions. 
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Figure 16. Several monodisperse gas lipospheres capable of carrying drug (circled in white) 
attached to human metastatic breast cancer cells (MDA-MB-231). The cells are labeled at 
low-passage density with MitoTracker Red, and the nucleus stained with Hoechst 33342. 
Scale bar is 100 µm. 
 
As shown in Figure 17, biotinylated gas lipospheres with the avidin linker bound to 
biotinylated MDA-MB-231 breast cancer cells are visible in fluorescence microscopy. It is 
possible to have multiple gas lipospheres bound to a single cell, and the binding efficiency 
depends largely on liposphere size. Gas lipospheres <10 lm in diameter were found to more 
favorably target the cells than larger vehicles. The vehicles remained bound through cell 
death, ~1 h into the experiment. Because of the possibility of an immunogenic response 
with avidin or Streptavidin, we anticipate an alternative conjugation method besides avidin-
biotin will be used for future targeted drug delivery to tumor vasculature or other target 
sites. 
 
Acoustic response 
From an m-mode ultrasound image of 12 echoes, as shown in Figure 18a, the 
acoustic response of 15 µm multilayer gas lipospheres can be determined. Average 
correlation was measured to be ~0.97, indicating that the echo signatures were nearly 
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identical. This is in contrast to previous measurements of commercially-available 
polydisperse contrast agents, which exhibit echo correlations on the order of 0.7. A 
comparison can be found in Figure 18b. The nearly identical signatures mean that we can 
optimize ultrasound concentration and drug-release parameters to affect all gas lipospheres 
similarly. In contrast, for a polydisperse drug delivery vehicle, ultrasound may be able to 
fragment a 5 µm vehicle but not a 10 µm vehicle due to the different acoustic parameters 
required to affect vehicles of different size and corresponding different resonant 
frequencies. Future experiments will study the acoustic parameters required to concentrate 
the vehicles with ultrasound radiation force and locally release drug payloads at the target 
site. 
 
 
Figure 17. Acoustic response of 15 µm multilayer gas lipospheres. (a) M-mode ultrasound 
image of 12 gas liposphere echoes, with a mean echo correlation of 0.97. (b) Echoes of 
individual gas lipospheres were more correlated for a monodisperse population produced 
with microfluidics compared with a standard polydisperse microbubble population 
produced with mechanical agitation. 
 
Conclusions 
With microfluidics technology, we can produce monodisperse multilayer gas 
lipospheres in a suitable size range for local injection into tumor sites. Their composition 
allows them to be both ultrasonically active and able to carry a large and precise drug 
payload to the target site. Precision engineered multilayer gas lipospheres are much more 
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consistent in their response to ultrasound radiation force. We expect this to directly 
translate into uniform drug release and improved imaging characteristics compared with 
polydisperse vehicles. 
Vehicles can be further developed by having very specific targeting ligands on the 
shell surface. As proof-of-concept, we produced vehicles containing biotin groups with 
avidin linkers on the shell for attachment to biotinylated breast cancer cells, and have 
demonstrated loading with a model drug Doxorubicin. Conjugating a cyclic-RGD (cyclo[Arg-
Gly- Asp]) peptide to the shell to enhance vehicle retention in tumor vasculature that over 
express the αvβ3 integrin is a possibility for targeted delivery. On binding, the narrow size 
distribution will enable consistent vehicle disruption at the lowest mechanical index (MI) 
possible.  
The controlled production of multilayer microbubble lipospheres using the 
microfluidic platform provides exciting opportunities for cancer research. We believe similar 
technology can be applied to generate vehicles that carry hydrophilic drugs as well. The 
incorporation of a small gas bubble within water or hydrophilic core contained within a 
secondary shell would make an acoustically-active drug delivery vehicle for hydrophilic 
molecules. A nice prospect is that when using these vehicles with ultrasound, we can expect 
to not only deliver and release chemotherapeutic-containing vehicles for therapeutic 
purposes with site-specificity and low toxicity, but also the acoustic activity of the vehicles 
will allow imaging of their distribution within the vasculature and estimation of tumor blood 
perfusion. 
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Chapter 4.   
Conclusions and future research 
 The work presented herein represents a preliminary investigation demonstrating several 
techniques which could enhance the effectiveness of therapeutic ultrasound and their use in a 
novel application.  MCAs were successfully shown to reach the posterior region of the eye via an 
injection into the anterior SCS and were characterized for the entire volume of the eye using 3D 
ultrasound.  Additionally, the delivery of a fluorescent dye was enhanced in tissues of interest 
with the 3D application of ARF, likely because of ultrasound mediated changes in permeability.  
The production of monodisperse MCAs capable of carrying hydrophobic therapeutic compounds 
was also demonstrated.  While production rates were low, the small volume of the eye 
represents an ideal platform for initial demonstration of drug delivery using microfluidic 
production of MCAs.   
 Several factors of drug delivery in the eye require further study; most importantly, the 
effect of active perfusion in the in vivo environment will have on drug diffusion and distribution.  
More minor areas of investigation include the effect of buoyancy on MCA distribution altered 
ocular pressures which may exist for an in vivo eye.  The use of ARF also requires a specialized 
transducer or acoustic setting in order to most effectively take advantage of this phenomenon. 
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